The dosage of blood p-tau231 or p-tau181 through either ECLIA-based or Simoa methods could substantially distinguish the NfL positive population, respectively, in non-AD (NfL+, p-tau −) versus AD (NfL +, p-tau +) pathophysiology of the putative NDD [35,43]. This evidence concerns the gene MAPT and Neurodevelopmental delay.